小鼠幼稚 CD4+ T 细胞体外分化为致病性 Th17 细胞
October 25th, 2024
该方案描述了幼稚 CD4 + T 细胞 在体外分化为致病性 Th17 细胞。具体来说，当与基于多参数流式细胞术的方法结合使用时，使用这种分化方法可以从初始 CD4+ T 细胞中获得 90% 纯度的致病性 Th17 细胞。
我们的研究目标是靶向 Th17 细胞的定向分化，我们的目标是探索一种简单的 Th17 细胞再引入分化的方法，该方法作为与某些疾病相关的 Th17 细胞相关的重新引入实验的传统条件。许多研究都提到了重新引入 Th17 细胞的方法，最近的研究集中在小分子抑制剂和其他刺激物上。然而，几乎所有研究的宫内诱导纯度都不稳定在 50% 以上许多新技术已被应用于 Th17 细胞的筛选和循环，例如 Th17 细胞的流式细胞术分选和 Th17 细胞的磁珠分选。
关键是，我们找到了一种简单的方法来诱导Th17细胞分化，通过向培养基中加入不同浓度的 ，其分化纯度可以接近90%我们的实验室，我们正在研究自停滞模型中亚氨基微环境的变化，包括免疫细胞的变化和免疫失衡的方向， 等等。
概述
该协议描述了一种方法，用于将na茂ve CD4 + T细胞在体外分化为致病性Th17细胞，达到90%的纯度。该方法利用多参数流式细胞术进行有效的细胞分析。
关键研究组成部分
科学领域
- 免疫学
- 细胞生物学
- 病理学
背景
- Th17细胞在自身免疫性疾病中起着至关重要的作用。
- 传统的Th17分化诱导方法通常产生低纯度。
- 最近的进展集中在小分子抑制剂以增强分化。
- 流式细胞术是分析细胞群体的关键技术。
研究目的
- 开发一种可靠的方法来诱导Th17细胞分化。
- 为研究目的实现分化Th17细胞的高纯度。
- 探索与Th17细胞相关的免疫微环境变化。
所用方法
- 从小鼠脾脏分离na茂ve CD4 + T细胞。
- 在特定培养基中使用激活鸡尾酒培养T细胞。
- 使用流式细胞术分析细胞分化。
- 使用磁珠分选来富集细胞。
主要结果
- 90%的na茂ve CD4 + T细胞成功分化为致病性Th17细胞。
- 流式细胞术确认了分化细胞的高纯度。
- 细胞培养条件被优化以实现有效分化。
- 观察到细胞形态变化，表明分化过程。
结论
- 所描述的方法为Th17细胞分化提供了一种简单而有效的方法。
- 高纯度的Th17细胞可以促进进一步研究自身免疫性疾病。
- 该协议可以适用于免疫学中的各种实验设置。
常见问题
Executive Industry Relevance
High-purity in vitro differentiation of pathogenic Th17 cells addresses a critical bottleneck in immunology-focused drug discovery, enabling more reliable target validation and mechanistic de-risking for autoimmune and inflammatory disease programs. Achieving approximately 90% differentiation purity supports predictive confidence in early-stage screening and functional studies, directly impacting portfolio triage and translational research continuity. This protocol enhances the reliability of disease-relevant cellular models for enterprise R&D pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables robust interrogation of Th17-driven disease mechanisms in autoimmune and inflammatory contexts.
- Supports functional target validation by providing high-purity, disease-relevant Th17 cell populations.
- Facilitates mechanistic de-risking and increases predictive confidence for early-stage programs.
Screening & Assay Development
- Provides standardized, reproducible Th17 cell preparations for downstream compound screening.
- Improves assay reliability by minimizing cellular heterogeneity and maximizing differentiation efficiency.
- Enables quantitative assessment of compound effects on pathogenic Th17 differentiation and function.
Translational & Preclinical Research
- Aligns in vitro Th17 models with disease-relevant immune microenvironments for translational studies.
- Supports continuity from discovery through preclinical validation by enabling consistent cellular readouts.
- Reduces biological risk in advancing immunomodulatory candidates targeting Th17 pathways.
Pipeline & Workflow Integration
This differentiation protocol fits within the early discovery to preclinical continuum, supporting both target validation and lead identification for autoimmune and inflammatory disease programs.
- Discovery Biology: Provides a platform for hypothesis testing and mechanistic studies of Th17-mediated pathology.
- Screening: Delivers reproducible, high-purity Th17 cells for assay development and compound evaluation.
- Analytics: Enables quantitative flow cytometry readouts to compare differentiation efficiency and functional outputs.
- Translational Research: Bridges in vitro findings with disease-relevant immune responses in preclinical models.
- Enterprise Reuse: Establishes a standardized protocol adaptable across multiple immunology research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in Th17-targeted research.
- Operational Value: Enhances standardization, reproducibility, and scalability of Th17 cell generation.
- Strategic Value: Improves go/no-go decision quality and capital efficiency in immunology portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of Th17-modulating candidates.
Implementation Considerations
- Requires expertise in primary cell isolation, magnetic bead sorting, and flow cytometry analysis.
- Demands access to cell culture infrastructure and multi-parameter flow cytometry platforms.
- Necessitates cross-team standardization of differentiation and analytical protocols.
- Adaptation may be needed for different mouse strains or disease models.
- Purity and yield may vary with input cell quality and reagent consistency.
Biopharma FAQs
Chapters in this video
0:00
Introduction
1:38
Isolation and Preparation of Mice Splenic Single‐Cell Suspension for Flow Cytometry Analysis
3:45
Purification and Analysis of Mice Naive CD4+ T‐Cells Using Magnetic Bead‐Based Negative Selection
5:57
In Vitro Induction of Pathogenic Th17 Cells into Naive CD4+ T‐Cells of Mice
